WO2000041708A1 - Composition pour le traitement de l'obesite et procede de traitement esthetique - Google Patents
Composition pour le traitement de l'obesite et procede de traitement esthetique Download PDFInfo
- Publication number
- WO2000041708A1 WO2000041708A1 PCT/FR2000/000065 FR0000065W WO0041708A1 WO 2000041708 A1 WO2000041708 A1 WO 2000041708A1 FR 0000065 W FR0000065 W FR 0000065W WO 0041708 A1 WO0041708 A1 WO 0041708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- green tea
- caffeine
- catechols
- tea extract
- mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/18—Extraction of water soluble tea constituents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
- A23F3/28—Drying or concentrating tea extract by spraying into a gas stream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to the general field of obesity treatment. It relates in particular to compositions for the curative and prophylactic treatment of obesity, but it also relates to the aesthetic treatment of a human being to improve his figure.
- the therapeutic objective in obesity is well defined: it is either to allow the subject to lose weight significantly, or to help the subject to keep a weight level as low as desirable-
- Nutritional approaches aim to reduce the intake of energy in the form of food. This can be done by drastically reducing energy intake or by replacing energy nutrients with others that are less so: such as non-digestible substitute fats, structured triglycerides with reduced assimilation or non-assimilable dietary fibers.
- Therapeutic approaches can have various targets.
- Reducing food intake may be the first goal. Reduction in food intake can be sought by the use of anorectic substances, whose short-term effects are shown, but whose duration of use is limited because of undesirable side effects. In fact, very few of these products are truly usable and their long-term effectiveness remains highly disputed. New molecules are being evaluated or could be in the near future, but their interest remains to be demonstrated.
- thermogenic substances acting at central or peripheral level.
- the use of these substances is still limited.
- a third objective is to reduce the assimilation of dietary lipids, and even possibly that of carbohydrates. This is a more recent approach, but one which is gaining increasing interest.
- a reduction in the assimilation of food lipids can be obtained either by a reduction in the activity of the digestive enzymes concerned, or by modifying the properties of the interfaces transporting the lipid molecules, emulsions, vesicles or micelles.
- tea for which the end of the stems is used, comprising the last two leaves and the bud. After harvesting, these leaves can be subjected to fermentation, resulting in a transformation of the chemical substances they contain and in particular catechols, which corresponds to black tea or else dried immediately, thus giving green tea.
- tea contains caffeine, the diuretic effect of which is well known. This diuretic effect is at the origin of the traditional use of green tea as a medicinal plant to promote renal elimination of water, whether in urinary disorders or in addition to weight loss diets. The presence of caffeine is also at the origin of the traditional use of tea in states of fatigue (asthenia).
- Green tea is also known for its anti-mutagenic and anti-carcinogenic effects. Green tea has been shown to significantly reduce the risk of colorectal, skin and breast cancer (Blot et al. 1997, Conney et al. 1997, Dreosti et al. 1997, Jankun et al. 1997, Ji et al. 1997).
- green tea as a diuretic is currently done in the form of herbal teas, liquid extracts, plant powder or extracts in capsules or tablets.
- green tea often combined with another diuretic plant, is generally used at a dose corresponding to 1 to 3 g of plant per day.
- thermogenesis we therefore understand the advantage of being able to permanently increase thermogenesis, especially during a low-calorie diet where it is lowered.
- Different chemicals stimulate thermogenesis such as nicotine, ephedrine, aspirin, caffeine, etc., but none of them has made it possible to produce a drug for the treatment of obesity in insofar as the doses necessary to obtain an increase in thermogenesis entailed significant side effects, incompatible with necessarily long-term treatment, generally extending over several months.
- compositions for the curative and prophylactic treatment of obesity comprising an extract of green tea, Camellia sinensis, rich in catechols.
- the present invention also relates to the use of an extract or powder of green tea endowed with anti-lipase and / or thermogenic properties, for the manufacture of a medicament intended for the curative and prophylactic treatment of obesity.
- the present invention finally extends to a method of aesthetic treatment of a human being to improve his figure, characterized in that it involves the oral administration of a green tea extract enriched in catechols to cause loss or maintain a weight level as low as desirable.
- the green tea extract contains from 20 to 50%, in particular from 20 to 30% by mass of catechols expressed in epigallocatechol gallate (GEGC).
- GEGC epigallocatechol gallate
- the catechol content expressed in epigallocatechol gallate (GEGC), is for example advantageously determined in the context of the present invention by the implementation of the analytical method described below. One operates by liquid chromatography.
- Caffeine stock solution 30 mg of caffeine are dissolved in methanol and made up to 100 ml with the same solvent.
- Control solution 1 ml of each mother solution is taken and made up to 10 ml with the same solvent.
- Chromatography can be performed using:
- a spectrophotometer set to 278 nm. 10 ⁇ l of each of the solutions are injected separately, at least 2 times. The sensitivity of the detector is adjusted so as to obtain peaks whose height represents at least 50% of the total scale of the recorder.
- the caffeine content, percent is calculated using the following expression:
- SCE area of the peak corresponding to caffeine in the chromatogram obtained with the solution to be examined
- SCT area of the peak corresponding to caffeine in the chromatogram obtained with the control solution
- MCE test sample of extract in the solution to be examined, expressed in grams
- MCT test portion of caffeine in the control solution, expressed in milligrams.
- the catechol content expressed in epigallocatechol gallate (GEGC), percent, is calculated using the following expression:
- ⁇ SE sum of the areas of the peaks (2-5-6-7-8) corresponding to the catechols in the chromatogram obtained with the solution to be examined
- MT test sample of GEGC in the control solution, expressed in milligrams.
- epigallocatechol gallate represents on average about 70% of all the catechols present in an extract of green tea, with a range between 50 and 90%.
- the green tea extract contains from 5 to 10% by mass of caffeine.
- the green tea extract has a ratio of the concentration of catechols to the concentration of caffeine of between 2 and 10.
- the green tea extract is titrated so as to allow the administration of a daily dose of 250 to 500 mg, preferably about 375 mg of catechols per day and 50 to 200 mg, preferably about 150 mg of caffeine per day.
- thermogenesis The increase in thermogenesis in rats with a green tea extract according to the invention was studied according to the following protocol:
- the oxygen consumption of the rats is measured after the administration of the test product.
- the energy expenditure being proportional to the consumption of oxygen, this technique makes it possible to measure the increase in thermogenesis, the basic metabolism and the muscular work being constant before and after treatment.
- the product tested was a green tea extract containing 24.7% catechols and 8.35% caffeine.
- thermogenesis in humans by a green tea extract according to the invention has also been determined.
- thermogenesis demonstrate the ability of a green tea extract according to the invention to significantly increase thermogenesis. This property is not linked to the caffeine content of the extract, since the administration of caffeine alone, at the same dose as that provided by the green tea extract, does not increase thermogenesis.
- Respiratory is not accompanied by an increase in urinary nitrogen excretion, allows to conclude that there is an increase in lipid oxidation, which is the goal sought in any treatment of obesity.
- thermogenesis in vitro work has been carried out to demonstrate the existence of a synergy between epigallocatechol gallate and caffeine. This work was carried out on an ex vivo pharmacological model of thermogenesis. The principle is to measure the oxygen consumption of a sample of brown rat adipose tissue; oxygen consumption is proportional to the thermogenesis induced in the adipose tissue by the different substances tested.
- thermogenic stimulation synergy for a concentration of 200 ⁇ M of GEGC and 100 ⁇ M of caffeine, ie a CEGC / caffeine ratio of 2.
- this ratio will preferably be between 2 and 10.
- Green tea contains on average 6 to 7% of catechols and 2 to 3% caffeine.
- This example is not limiting and other extraction processes making it possible to obtain an extract sufficiently rich in catechols can be implemented, in particular by varying the proportions of water and ethanol, or by using other solvents such as water, ethyl acetate, methanol, etc., alone or combined in them.
- the choice of solvents used will make it possible to vary the catechol and caffeine contents, the objective being a high content of catechols, since the catechols are mainly at the origin of the pharmacological properties demonstrated above.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Tea And Coffee (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30537/00A AU772464B2 (en) | 1999-01-14 | 2000-01-14 | Composition for treating obesity and aesthetic treatment method |
DE60000259T DE60000259T2 (de) | 1999-01-14 | 2000-01-14 | Grüntee-extrakte enthaltend catechole und koffein |
MXPA01007191A MXPA01007191A (es) | 1999-01-14 | 2000-01-14 | Composicion para tratar obesidad y metodo de tratamiento estetico. |
IL14429700A IL144297A0 (en) | 1999-01-14 | 2000-01-14 | Composition for treating obesity and aesthetic treatment method |
US09/601,019 US6814986B1 (en) | 1999-01-14 | 2000-01-14 | Composition for treating obesity and esthetic treatment process |
AT00900573T ATE220326T1 (de) | 1999-01-14 | 2000-01-14 | Grüntee-extrakte enthaltend catechole und koffein |
PL00350300A PL350300A1 (en) | 1999-01-14 | 2000-01-14 | Composition for treating obesity and aesthetic treatment method |
CA002323711A CA2323711A1 (fr) | 1999-01-14 | 2000-01-14 | Composition pour le traitement de l'obesite et procede de traitement esthetique |
BR0007539-6A BR0007539A (pt) | 1999-01-14 | 2000-01-14 | Composição para o tratamento curativo e profilático da obesidade, utilização de um extrato de chá verde ou de um pó de chá verde, e, processo de tratamento estético de um ser humano para melhorar sua silhueta |
EP00900573A EP1098657B1 (fr) | 1999-01-14 | 2000-01-14 | Extraits de the vert contenant des catechols et de la cafeine |
JP2000593318A JP2002534474A (ja) | 1999-01-14 | 2000-01-14 | 肥満治療用組成物及びエステティック処置プロセス |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/00328 | 1999-01-14 | ||
FR9900328A FR2788438B1 (fr) | 1999-01-14 | 1999-01-14 | Composition pour le traitement de l'obesite et procede de traitement esthetique |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/601,019 A-371-Of-International US6814986B1 (en) | 1999-01-14 | 2000-01-14 | Composition for treating obesity and esthetic treatment process |
US10/274,888 Division US6830765B2 (en) | 1999-01-14 | 2002-10-22 | Green tea extract for treating obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000041708A1 true WO2000041708A1 (fr) | 2000-07-20 |
Family
ID=9540842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000065 WO2000041708A1 (fr) | 1999-01-14 | 2000-01-14 | Composition pour le traitement de l'obesite et procede de traitement esthetique |
Country Status (18)
Country | Link |
---|---|
US (2) | US6814986B1 (fr) |
EP (1) | EP1098657B1 (fr) |
JP (1) | JP2002534474A (fr) |
KR (1) | KR100662116B1 (fr) |
CN (1) | CN1339967A (fr) |
AT (1) | ATE220326T1 (fr) |
AU (1) | AU772464B2 (fr) |
BR (1) | BR0007539A (fr) |
CA (1) | CA2323711A1 (fr) |
DE (1) | DE60000259T2 (fr) |
ES (1) | ES2177506T3 (fr) |
FR (1) | FR2788438B1 (fr) |
IL (1) | IL144297A0 (fr) |
MX (1) | MXPA01007191A (fr) |
PL (1) | PL350300A1 (fr) |
RU (1) | RU2242984C2 (fr) |
WO (1) | WO2000041708A1 (fr) |
ZA (1) | ZA200105786B (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060319A2 (fr) * | 2000-02-18 | 2001-08-23 | Arch Development Corporation | Composes contenant du benzene polyhydroxyle |
US6485710B2 (en) * | 2000-12-27 | 2002-11-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
US6610277B2 (en) * | 2000-12-27 | 2003-08-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
US6610749B2 (en) | 2000-02-18 | 2003-08-26 | Arch Development Corporation | Polyhydroxylated benzene-containing compounds |
WO2004064542A1 (fr) * | 2003-01-17 | 2004-08-05 | Institut Phytoceutic | Composition pour une administration par voie orale contenant des capsaicinoïdes |
BG1004U1 (bg) * | 2007-01-26 | 2008-02-29 | Дойчин ДОЙЧИНОВ | Хранителна добавка |
US20080187606A1 (en) * | 2001-12-12 | 2008-08-07 | Min-Young Kim | Antiobesity composition |
US7739664B2 (en) | 2002-10-17 | 2010-06-15 | International Business Machines Corporation | Collection and detection of differences of values of expressions/variables when debugging a computer process |
US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
US7867526B2 (en) * | 2005-04-21 | 2011-01-11 | Ideasphere, Inc. | Composition for weight reduction comprising capsaicin, green tea extract, L-tyrosine and caffeine |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842425B1 (fr) * | 2002-07-16 | 2005-04-08 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse |
US20040077556A1 (en) * | 2002-04-22 | 2004-04-22 | Robert Chinery | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
KR100496622B1 (ko) * | 2002-04-29 | 2005-06-29 | (주) 김형민한약연구소 | 비만 억제를 위한 알콜 발효 식품 또는 약학적 조성물 및그의 제조방법 |
US20030220351A1 (en) * | 2002-05-24 | 2003-11-27 | Gilbert Gonzales | Enteric coated caffeine tablet |
US20040096484A1 (en) * | 2002-11-19 | 2004-05-20 | Tyrrell David J. | Antioxidant-containing wipes and absorbent products for improving skin health |
EP1744774A4 (fr) * | 2004-04-30 | 2009-08-05 | New Hc Formulations Ltd | Composition nutritionnelle permettant de perdre du poids, de bruler des calories, d'augmenter la thermogenese, de favoriser le metabolisme energetique et/ou de suprrimer l'appetit |
KR100718161B1 (ko) * | 2004-06-18 | 2007-05-15 | 한국식품연구원 | 항비만용 리파제 저해제 및 용도 |
JP2006016367A (ja) * | 2004-07-05 | 2006-01-19 | Suntory Ltd | リパーゼ阻害剤 |
US20080209473A1 (en) * | 2004-09-02 | 2008-08-28 | Koninklijke Philips Electronics, N.V. | Method and Apparatus for Building an Electronic Program Guide Based on Channel Profiles |
US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
CA2628289C (fr) | 2005-11-04 | 2016-04-12 | Iovate T. & P. Inc. | Composition a base de plantes pour le controle ponderal |
US20070178176A1 (en) * | 2006-02-02 | 2007-08-02 | Chithan Kandaswami | Composition and method for promoting weight loss |
US7989009B2 (en) * | 2006-02-02 | 2011-08-02 | Advocare International, L.P. | Composition and method for promoting weight loss |
CA2656997A1 (fr) * | 2006-03-31 | 2008-10-11 | Dsm Ip Assets B.V. | Nouvelle utilisation de composes et de combinaisons de composes pour ameliorer l'aspect physique |
BG1005U1 (bg) * | 2007-01-26 | 2008-02-29 | Стоян ДОЙЧИНОВ | Хранителна добавка |
EP2186418A4 (fr) * | 2007-08-30 | 2011-11-16 | Kao Corp | Boisson en poudre instantanée |
CN102170798B (zh) | 2008-10-03 | 2013-06-12 | 西格马食品可变资本有限公司 | 用于促进对总胆固醇和ldl胆固醇的控制和/或体重减轻和/或生热作用的组合物 |
US20100215782A1 (en) * | 2008-10-22 | 2010-08-26 | Metaproteomics, Llc | Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis |
KR20100124519A (ko) * | 2009-05-19 | 2010-11-29 | (주)아모레퍼시픽 | 녹차 추출물을 함유하는 조성물 |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
RU2531928C1 (ru) * | 2013-10-21 | 2014-10-27 | Федеральное государственное бюджетное учреждение "Научный центр клинической и экспериментальной медицины" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦКЭМ" СО РАМН) | Способ коррекции ожирения гиноидного типа |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
CN107029237B (zh) * | 2016-02-04 | 2021-06-25 | 康建胜 | 产热增强化合物增强去甲肾上腺素类化合物诱导褐色脂肪细胞产热的应用 |
CN107638569A (zh) * | 2016-07-21 | 2018-01-30 | 上海聿健生物科技有限公司 | 增强褐色脂肪细胞产热效率的方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60114153A (ja) * | 1983-11-26 | 1985-06-20 | Osaka Chem Lab | 茶葉抽出物含有食品組成物 |
EP0456023A1 (fr) * | 1990-05-09 | 1991-11-13 | Societe Des Produits Nestle S.A. | Procédé d'obtention de complexes de catechines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59219384A (ja) * | 1983-05-30 | 1984-12-10 | Mitsui Norin Kk | 天然抗酸化剤の製造方法 |
JPS60114158A (ja) | 1983-11-25 | 1985-06-20 | House Food Ind Co Ltd | 揚げそばの製造法 |
JP3018013B2 (ja) * | 1989-10-19 | 2000-03-13 | 三井農林株式会社 | α―アミラーゼ活性阻害剤 |
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
US5605929A (en) * | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
JP2598873B2 (ja) * | 1993-08-25 | 1997-04-09 | 株式会社ロッテ | リパーゼ阻害剤およびこれを添加した飲食品 |
US5776756A (en) * | 1995-08-31 | 1998-07-07 | Toyo Hakko Co., Ltd. | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity |
JP3259758B2 (ja) * | 1996-06-21 | 2002-02-25 | 東洋精糖株式会社 | 飲食物およびその製造方法 |
-
1999
- 1999-01-14 FR FR9900328A patent/FR2788438B1/fr not_active Expired - Fee Related
-
2000
- 2000-01-14 WO PCT/FR2000/000065 patent/WO2000041708A1/fr active IP Right Grant
- 2000-01-14 CA CA002323711A patent/CA2323711A1/fr not_active Abandoned
- 2000-01-14 AU AU30537/00A patent/AU772464B2/en not_active Ceased
- 2000-01-14 ES ES00900573T patent/ES2177506T3/es not_active Expired - Lifetime
- 2000-01-14 RU RU2001122719/15A patent/RU2242984C2/ru not_active IP Right Cessation
- 2000-01-14 AT AT00900573T patent/ATE220326T1/de not_active IP Right Cessation
- 2000-01-14 EP EP00900573A patent/EP1098657B1/fr not_active Revoked
- 2000-01-14 IL IL14429700A patent/IL144297A0/xx unknown
- 2000-01-14 JP JP2000593318A patent/JP2002534474A/ja active Pending
- 2000-01-14 BR BR0007539-6A patent/BR0007539A/pt not_active IP Right Cessation
- 2000-01-14 DE DE60000259T patent/DE60000259T2/de not_active Expired - Fee Related
- 2000-01-14 US US09/601,019 patent/US6814986B1/en not_active Expired - Lifetime
- 2000-01-14 CN CN00803770A patent/CN1339967A/zh active Pending
- 2000-01-14 MX MXPA01007191A patent/MXPA01007191A/es unknown
- 2000-01-14 KR KR1020017008866A patent/KR100662116B1/ko not_active IP Right Cessation
- 2000-01-14 PL PL00350300A patent/PL350300A1/xx not_active Application Discontinuation
-
2001
- 2001-07-13 ZA ZA200105786A patent/ZA200105786B/en unknown
-
2002
- 2002-10-22 US US10/274,888 patent/US6830765B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60114153A (ja) * | 1983-11-26 | 1985-06-20 | Osaka Chem Lab | 茶葉抽出物含有食品組成物 |
EP0456023A1 (fr) * | 1990-05-09 | 1991-11-13 | Societe Des Produits Nestle S.A. | Procédé d'obtention de complexes de catechines |
Non-Patent Citations (2)
Title |
---|
ADRIAN G. PASCHKA ET AL.: "INDUCTION OF APOPTOSIS IN PROSTATE CANCER CELL LINES BY THE GREEN TEA COMPONENT, (-)-EPIGALLOCATECHIN-3-GALLATE.", CANCER LETTERS, vol. 130, no. 1-2, 14 August 1998 (1998-08-14), NEW YORK, NY, US, pages 1 - 7, XP002117137, ISSN: 0304-3835 * |
PATENT ABSTRACTS OF JAPAN vol. 009, no. 260 (C - 309) 17 October 1985 (1985-10-17) * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060319A3 (fr) * | 2000-02-18 | 2002-03-21 | Arch Dev Corp | Composes contenant du benzene polyhydroxyle |
US6610749B2 (en) | 2000-02-18 | 2003-08-26 | Arch Development Corporation | Polyhydroxylated benzene-containing compounds |
WO2001060319A2 (fr) * | 2000-02-18 | 2001-08-23 | Arch Development Corporation | Composes contenant du benzene polyhydroxyle |
US6485710B2 (en) * | 2000-12-27 | 2002-11-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
US6610277B2 (en) * | 2000-12-27 | 2003-08-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
US20080187606A1 (en) * | 2001-12-12 | 2008-08-07 | Min-Young Kim | Antiobesity composition |
US9155773B2 (en) * | 2001-12-12 | 2015-10-13 | Angiolab, Inc. | Antiobesity composition |
US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
US7739664B2 (en) | 2002-10-17 | 2010-06-15 | International Business Machines Corporation | Collection and detection of differences of values of expressions/variables when debugging a computer process |
US7892582B2 (en) | 2003-01-17 | 2011-02-22 | Institut Phytoceutic | Composition for oral administration containing capsaicinoids |
WO2004064542A1 (fr) * | 2003-01-17 | 2004-08-05 | Institut Phytoceutic | Composition pour une administration par voie orale contenant des capsaicinoïdes |
US7867526B2 (en) * | 2005-04-21 | 2011-01-11 | Ideasphere, Inc. | Composition for weight reduction comprising capsaicin, green tea extract, L-tyrosine and caffeine |
BG1004U1 (bg) * | 2007-01-26 | 2008-02-29 | Дойчин ДОЙЧИНОВ | Хранителна добавка |
Also Published As
Publication number | Publication date |
---|---|
ZA200105786B (en) | 2002-02-27 |
KR100662116B1 (ko) | 2006-12-27 |
IL144297A0 (en) | 2002-05-23 |
MXPA01007191A (es) | 2003-07-21 |
FR2788438A1 (fr) | 2000-07-21 |
FR2788438B1 (fr) | 2003-10-03 |
US20030104081A1 (en) | 2003-06-05 |
AU3053700A (en) | 2000-08-01 |
EP1098657A1 (fr) | 2001-05-16 |
RU2242984C2 (ru) | 2004-12-27 |
DE60000259D1 (de) | 2002-08-14 |
US6814986B1 (en) | 2004-11-09 |
ES2177506T3 (es) | 2002-12-16 |
JP2002534474A (ja) | 2002-10-15 |
BR0007539A (pt) | 2001-10-16 |
US6830765B2 (en) | 2004-12-14 |
CA2323711A1 (fr) | 2000-07-20 |
DE60000259T2 (de) | 2004-04-15 |
EP1098657B1 (fr) | 2002-07-10 |
ATE220326T1 (de) | 2002-07-15 |
KR20010103739A (ko) | 2001-11-23 |
PL350300A1 (en) | 2002-12-02 |
CN1339967A (zh) | 2002-03-13 |
AU772464B2 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1098657B1 (fr) | Extraits de the vert contenant des catechols et de la cafeine | |
WO2000054610A1 (fr) | Complement alimentaire et procede de traitement cosmetique a base d'un extrait de raisin riche en polyphenols | |
EP2146708B1 (fr) | Composition a activité lipolytique, son procédé d'obtention et utilisation de la composition. | |
EP2010012A1 (fr) | Utilisation du safran et/ou du safranal et/ou de la crocine et/ou de la picrocrocine et/ou de leurs derives en tant qu'agent de satiete pour le traitement de la surcharge ponderale | |
EP1377183B1 (fr) | Preparation a base de cactaceae ayant la propriete de fixer les graisses, et procede d'obtention d'une telle preparation | |
FR3080989A1 (fr) | Composition liquide comprenant un extrait de feuilles de cassis et du jus de pomme concentre | |
JP5609834B2 (ja) | リパーゼ阻害剤 | |
EP1218021B1 (fr) | Extraits de branches de pommiers utiles en dermocosmetologie et leur procede de preparation | |
JPH10508880A (ja) | 糖尿病用医薬組成物 | |
EP3426277A1 (fr) | Extrait de safran pour le traitement des troubles du sommeil | |
EP3027064B1 (fr) | Composition pharmaceutique, diététique ou alimentaire liquide ou semi-liquide dépourvue d'amertume contenant un sel d'arginine | |
WO2005023234A1 (fr) | Utilisation de l’acide nor-dihydroguaiaretique en tant qu’inhibiteur de la formation adipocytaire humaine | |
FR2931664A1 (fr) | Compositions a base de plantes et utilisations | |
EP2197437A1 (fr) | Utilisation de l'oleocanthal pour le traitement des troubles du metabolisme lipidique | |
JP2007176837A (ja) | 痩身用組成物 | |
Ollier | Rooibos (red bush tea) | |
BE888697A (fr) | Comprime de theophylline a liberation prolongee | |
FR2951908A1 (fr) | Composition comprenant une poudre de nopal et de la levure de riz rouge et complement alimentaire comprenant cette composition | |
KR19990027764A (ko) | 동맥경화억제용 약제조성물 | |
FR2873292A1 (fr) | Composes et methodes pour controler la prise d'alcool |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00803770.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2323711 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000900573 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09601019 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: (EXCEPT CA, JP, US, EP (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)) |
|
WWP | Wipo information: published in national office |
Ref document number: 2000900573 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 144297 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/05786 Country of ref document: ZA Ref document number: PA/a/2001/007191 Country of ref document: MX Ref document number: 30537/00 Country of ref document: AU Ref document number: 200105786 Country of ref document: ZA Ref document number: 1020017008866 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513479 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017008866 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000900573 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 30537/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017008866 Country of ref document: KR |